- Home
- RCS vs VNDA Comparison
RCS vs VNDA Comparison
Compare RCS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCS | VNDA |
|---|---|---|
| Founded | 1994 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.9M | 289.0M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | RCS | VNDA |
|---|---|---|
| Price | $6.71 | $6.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 141.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 10-29-2025 |
| Dividend Yield | ★ 10.12% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $4.51 | $3.81 |
| 52 Week High | $6.31 | $6.88 |
Technical Indicators
Market Signals| Indicator | RCS | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 42.50 | 66.91 |
| Support Level | $6.64 | $6.15 |
| Resistance Level | $7.04 | $6.88 |
| Average True Range (ATR) | 0.14 | 0.41 |
| MACD | 0.03 | 0.15 |
| Stochastic Oscillator | 30.77 | 84.98 |
Price Performance
Historical ComparisonAbout RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.